48 research outputs found
Digitaldlsorter: Deep-Learning on scRNA-Seq to Deconvolute Gene Expression Data
The development of single cell transcriptome sequencing has allowed researchers the possibility to dig inside the role of the individual cell types in a plethora of disease scenarios. It also expands to the whole transcriptome what before was only possible for a few tenths of antibodies in cell population analysis. More importantly, it allows resolving the permanent question of whether the changes observed in a particular bulk experiment are a consequence of changes in cell type proportions or an aberrant behavior of a particular cell type. However, single cell experiments are still complex to perform and expensive to sequence making bulk RNA-Seq experiments yet more common. scRNA-Seq data is proving highly relevant information for the characterization of the immune cell repertoire in different diseases ranging from cancer to atherosclerosis. In particular, as scRNA-Seq becomes more widely used, new types of immune cell populations emerge and their role in the genesis and evolution of the disease opens new avenues for personalized immune therapies. Immunotherapy have already proven successful in a variety of tumors such as breast, colon and melanoma and its value in other types of disease is being currently explored. From a statistical perspective, single-cell data are particularly interesting due to its high dimensionality, overcoming the limitations of the "skinny matrix" that traditional bulk RNA-Seq experiments yield. With the technological advances that enable sequencing hundreds of thousands of cells, scRNA-Seq data have become especially suitable for the application of Machine Learning algorithms such as Deep Learning (DL). We present here a DL based method to enumerate and quantify the immune infiltration in colorectal and breast cancer bulk RNA-Seq samples starting from scRNA-Seq. Our method makes use of a Deep Neural Network (DNN) model that allows quantification not only of lymphocytes as a general population but also of specific CD8+, CD4Tmem, CD4Th and CD4Tregs subpopulations, as well as B-cells and Stromal content. Moreover, the signatures are built from scRNA-Seq data from the tumor, preserving the specific characteristics of the tumor microenvironment as opposite to other approaches in which cells were isolated from blood. Our method was applied to synthetic bulk RNA-Seq and to samples from the TCGA project yielding very accurate results in terms of quantification and survival prediction.This work was supported by the European Union’s Horizon 2020 research and innovation program under grant agreement number 633592 (Project APERIM: Advanced bioinformatics platform for personalized cancer immunotherapy). We thank Francesca Finotello and Zlatko Trajanoski for fruitful discussions and to the CNIC Bioinformatics Unit members for continuous support and work. The CNIC is supported by MEIC and the ProCNIC Foundation, and is a Severo Ochoa Center of Excellence (MEIC award SEV-2015-0505).S
Dispatched mediates Hedgehog basolateral release to form the long-range morphogenetic gradient in the Drosophila wing disk epithelium
Hedgehog (Hh) moves from the producing cells to regulate the growth and development of distant cells in a variety of tissues. Here, we have investigated the mechanism of Hh release from the producing cells to form a morphogenetic gradient in the Drosophila wing imaginal disk epithelium. We describe that Hh reaches both apical and basolateral plasma membranes, but the apical Hh is subsequently internalized in the producing cells and routed to the basolateral surface, where Hh is released to form a longrange gradient. Functional analysis of the 12-transmembrane protein Dispatched, the glypican Dally-like (Dlp) protein, and the Iglike and FNNIII domains of protein Interference Hh (Ihog) revealed that Dispatched could be involved in the regulation of vesicular trafficking necessary for basolateral release of Hh, Dlp, and Ihog. We also show that Dlp is needed in Hh-producing cells to allow for Hh release and that Ihog, which has been previously described as an Hh coreceptor, anchors Hh to the basolateral part of the disk epithelium.This work was supported by Grants BFU2005-04183 and BFU2008-03320/BMC and by Consolider Program CDS 2007-00008 from the Spanish MICINN, by Marie Curie RTN FP6 (RTN 035528-2) and FP7 (ITN 238186) projects, and by an institutional grant from the Fundación Areces to I.G. It was also financially supported by fellowships awarded by the Junta para la Ampliación de Estudios-Consejo Superior de Investigaciones Cientificas program (to N.G. and A.C.), a Juan de la Cierva fellowship from the Spanish MICINN (to A.B.), a Marie Curie RTN 035528-2 FP6 contract (to E.M.), a contract from the Spanish MICINN (to L.D.), and the senior researcher Programa Amarouto from Severo Ochoa Fondation program of the Comunidad Autónoma de Madrid (G.A.)Peer Reviewe
Wt1 transcription factor impairs cardiomyocyte specification and drives a phenotypic switch from myocardium to epicardium.
During development, the heart grows by addition of progenitor cells to the poles of the primordial heart tube. In the zebrafish, Wilms tumor 1 transcription factor a (wt1a) and b (wt1b) genes are expressed in the pericardium, at the venous pole of the heart. From this pericardial layer, the proepicardium emerges. Proepicardial cells are subsequently transferred to the myocardial surface and form the epicardium, covering the myocardium. We found that while wt1a and wt1b expression is maintained in proepicardial cells, it is downregulated in pericardial cells that contributes cardiomyocytes to the developing heart. Sustained wt1b expression in cardiomyocytes reduced chromatin accessibility of specific genomic loci. Strikingly, a subset of wt1a- and wt1b-expressing cardiomyocytes changed their cell-adhesion properties, delaminated from the myocardium and upregulated epicardial gene expression. Thus, wt1a and wt1b act as a break for cardiomyocyte differentiation, and ectopic wt1a and wt1b expression in cardiomyocytes can lead to their transdifferentiation into epicardial-like cells.NM has been funded by SNF grant 320030E-164245 and ERC Consolidator grant
2018 819717. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the
Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation and is a
Severo Ochoa Center of Excellence (SEV-2015-0505). Benoît Zuber is supported by
SNF grant 179520 and ERA-NET NEURON grant 185536. M.O. was supported by
SNF grant PCEFP3_186993.S
Cholesterol lowering depletes atherosclerotic lesions of smooth muscle cell-derived fibromyocytes and chondromyocytes
S
CXCL6 is an important paracrine factor in the pro-angiogenic human cardiac progenitor-like cell secretome
Studies in recent years have established that the principal effects in cardiac cell therapy are associated with paracrine/autocrine factors. We combined several complementary techniques to define human cardiac progenitor cell (CPC) secretome constituted by 914 proteins/genes; 51% of these are associated with the exosomal compartment. To define the set of proteins specifically or highly differentially secreted by CPC, we compared human mesenchymal stem cells and dermal fibroblasts; the study defined a group of growth factors, cytokines and chemokines expressed at high to medium levels by CPC. Among them, IL-1, GROa (CXCL1), CXCL6 (GCP2) and IL-8 are examples whose expression was confirmed by most techniques used. ELISA showed that CXCL6 is significantly overexpressed in CPC conditioned medium (CM) (18- to 26-fold) and western blot confirmed expression of its receptors CXCR1 and CXCR2. Addition of anti-CXCL6 completely abolished migration in CPC-CM compared with anti-CXCR2, which promoted partial inhibition, and anti-CXCR1, which was inefficient. Anti-CXCL6 also significantly inhibited CPC CM angiogenic activity. In vivo evaluation also supported a relevant role for angiogenesis. Altogether, these results suggest a notable angiogenic potential in CPC-CM and identify CXCL6 as an important paracrine factor for CPC that signals mainly through CXCR2.This study was supported by funding from the European Commission (HEALTH-2009_242038) and by grants from the Spanish Ministry of Science and Innovation (SAF2012-34327 and SAF2015-70882-R to AB and BIO2012-37926 and BIO2015-67580-P to JV), the Research Program of the Comunidad Autónoma de Madrid (S2010/BMD-2420) and the Instituto de Salud Carlos III (RETICS-RD12/0019/0018 to AB and RETICS-RD12/0042/0056 to JV).S
Pluripotency factors regulate the onset of Hox cluster activation in the early embryo
Pluripotent cells are a transient population of the mammalian embryo dependent on transcription factors, such as OCT4 and NANOG, which maintain pluripotency while suppressing lineage specification. However, these factors are also expressed during early phases of differentiation, and their role in the transition from pluripotency to lineage specification is largely unknown. We found that pluripotency factors play a dual role in regulating key lineage specifiers, initially repressing their expression and later being required for their proper activation. We show that Oct4 is necessary for activation of HoxB genes during differentiation of embryonic stem cells and in the embryo. In addition, we show that the HoxB cluster is coordinately regulated by OCT4 binding sites located at the 3′ end of the cluster. Our results show that core pluripotency factors are not limited to maintaining the precommitted epiblast but are also necessary for the proper deployment of subsequent developmental programs
Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation
Here we explored the role of interleukin-1β (IL-1β) repressor cytokine, IL-1 receptor antagonist (IL-1rn), in both healthy and abnormal hematopoiesis. Low IL-1RN is frequent in acute myeloid leukemia (AML) patients and represents a prognostic marker of reduced survival. Treatments with IL-1RN and the IL-1β monoclonal antibody canakinumab reduce the expansion of leukemic cells, including CD34+ progenitors, in AML xenografts. In vivo deletion of IL-1rn induces hematopoietic stem cell (HSC) differentiation into the myeloid lineage and hampers B cell development via transcriptional activation of myeloid differentiation pathways dependent on NFκB. Low IL-1rn is present in an experimental model of pre-leukemic myelopoiesis, and IL-1rn deletion promotes myeloproliferation, which relies on the bone marrow hematopoietic and stromal compartments. Conversely, IL-1rn protects against pre-leukemic myelopoiesis. Our data reveal that HSC differentiation is controlled by balanced IL-1β/IL-1rn levels under steady-state, and that loss of repression of IL-1β signaling may underlie pre-leukemic lesion and AML progression
Pluripotency factors regulate the onset of Hox cluster activation in the early embryo
Pluripotent cells are a transient population of the mammalian embryo dependent on transcription factors, such as OCT4 and NANOG, which maintain pluripotency while suppressing lineage specification. However, these factors are also expressed during early phases of differentiation, and their role in the transition from pluripotency to lineage specification is largely unknown. We found that pluripotency factors play a dual role in regulating key lineage specifiers, initially repressing their expression and later being required for their proper activation. We show that Oct4 is necessary for activation of HoxB genes during differentiation of embryonic stem cells and in the embryo. In addition, we show that the HoxB cluster is coordinately regulated by OCT4 binding sites located at the 3′ end of the cluster. Our results show that core pluripotency factors are not limited to maintaining the precommitted epiblast but are also necessary for the proper deployment of subsequent developmental programs.This work was funded by the Spanish government (grants BFU2017-84914-P and PID2020-115755GB-I00 to M.M.; BFU2016-74961-P and BFU2016-81887-REDT to J.L.G.-S.), the Andalusian government (grant BIO-396 to J.L.G.-S.), and the European Research Council (ERC; grant agreement 740041 to J.L.G.-S.). M.T. held Juan de la Cierva fellowships from the Spanish government (FJCI-2017-31791 and IJC2019-038897-I), R.R. and R.D.A. held FPU fellowships from the government, and J.V. was the recipient of a “La Caixa” fellowship. Work in the laboratory of J.L.G.-S. was supported by a María de Maetzu Unit of Excellence Grant (MDM-2016-0687) to the Department of Gene Regulation and Morphogenesis of the CABD. The CBMSO is supported by an institutional grant from the Fundación Ramon Areces, and the CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). : With funding from the Spanish government through the ‘Severo Ochoa Centre of
Excellence’ accreditation (CEX2020-001041-S)
Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation.
Here we explored the role of interleukin-1β (IL-1β) repressor cytokine, IL-1 receptor antagonist (IL-1rn), in both healthy and abnormal hematopoiesis. Low IL-1RN is frequent in acute myeloid leukemia (AML) patients and represents a prognostic marker of reduced survival. Treatments with IL-1RN and the IL-1β monoclonal antibody canakinumab reduce the expansion of leukemic cells, including CD34+ progenitors, in AML xenografts. In vivo deletion of IL-1rn induces hematopoietic stem cell (HSC) differentiation into the myeloid lineage and hampers B cell development via transcriptional activation of myeloid differentiation pathways dependent on NFκB. Low IL-1rn is present in an experimental model of pre-leukemic myelopoiesis, and IL-1rn deletion promotes myeloproliferation, which relies on the bone marrow hematopoietic and stromal compartments. Conversely, IL-1rn protects against pre-leukemic myelopoiesis. Our data reveal that HSC differentiation is controlled by balanced IL-1β/IL-1rn levels under steady-state, and that loss of repression of IL-1β signaling may underlie pre-leukemic lesion and AML progression.We thank K. Tasken, J. Saarela and the NCMM at the University of
Oslo (UiO), S. Kanse (UiO) and B. Smedsrød (UiT), for access to
facilities. We acknowledge Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital (Bergen, Norway)
and R. Hovland for karyotyping, FISH, translocation and DNA analyses of AML and MDS patients included in this study, and
Department of Pathology, Oslo University Hospital (Oslo, Norway)
and S. Spetalen for deep sequencing. L.M. Gonzalez, L.T. Eliassen,
X. Zhang, M. Ristic and other members of L. Arranz group, O.P.
Rekvig, R. Doohan, L.D. Håland, M.I. Olsen, A. Urbanucci, J. Landskron, K.B. Larsen, R.A. Lyså and UiT Advanced Microscopy Core
Facility, UiO and UiT Comparative Medicine Units, for assistance.
P. Garcia and S. Mendez-Ferrer for providing NRASG12D and Nes-gfp
mice, respectively. P. Garcia and L. Kurian for careful reading of the manuscript. E. Tenstad (Science Shaped) for artwork in schematics.
We would also like to thank the AML and MDS patients, and healthy
volunteers, who donated biological samples. Our work is supported by a joint meeting grant of the Northern Norway Regional
Health Authority, the University Hospital of Northern Norway (UNN)
and UiT (Strategisk-HN06-14), Young Research Talent grants from
the Research Council of Norway, (Stem Cell Program, 247596;
FRIPRO Program, 250901), and grants from the Norwegian Cancer
Society (6765150), the Northern Norway Regional Health Authority
(HNF1338-17), and the Aakre-Stiftelsen Foundation (2016/9050) to
L.A. Vav-Cre NRASG12D experiments were supported by NIH grant
R01CA152108 to J.Z.S
Incongruence between transcriptional and vascular pathophysiological cell states
Research in R.B.’s laboratory was supported by the European Research
Council Starting Grant AngioGenesHD (638028) and Consolidator
Grant AngioUnrestUHD (101001814), the CNIC Intramural Grant
Program Severo Ochoa (11-2016-IGP-SEV-2015-0505), the Ministerio
de Ciencia e Innovación (MCIN) (SAF2013-44329-P, RYC-2013-
13209, and SAF2017-89299-P) and ‘La Caixa’ Banking Foundation
(HR19-00120). J.V.’s laboratory was supported by MCIN (PGC2018-
097019-B-I00 and PID2021-122348NB-I00) and La Caixa (HR17-00247
and HR22-00253). K.G.’s laboratory was supported by Knut and
Alice Wallenberg Foundation (2020.0057) and Vetenskapsrådet
(2021-04896). The CNIC is supported by Instituto de Salud Carlos
III, MCIN, and the Pro CNIC Foundation, and is a Severo Ochoa
Center of Excellence (grant CEX2020-001041-S funded by MCIN/
AEI/10.13039/501100011033). Microscopy experiments were
performed at the Microscopy and Dynamic Imaging Unit, CNIC,
ICTS-ReDib, co-funded by MCIN/AEI/10.13039/501100011033 and
FEDER ‘Una manera de hacer Europa’ (ICTS-2018-04-CNIC-16). M.F.-C.
was supported by PhD fellowships from La Caixa (CX_E-2015-01)
and Boehringer Ingelheim travel grants. S.M. was supported by the
Austrian Science Fund (J4358). A.R. was supported by the Youth
Employment Initiative (PEJD-2019-PRE/BMD-16990). L.G.-O. was
supported by the Spanish Ministry of Economy and Competitiveness
(PRE2018-085283). We thank S. Bartlett (CNIC) for English editing,
as well as the members of the Transgenesis, Microscopy, Genomics,
Citometry and Bioinformatic units at CNIC. We also thank F. Radtke
(Swiss Institute for Experimental Cancer Research), R. H. Adams (Max
Planck Institute for Molecular Biomedicine), F. Alt (Boston Children’s
Hospital, Harvard Medical School), T. Honjo (Kyoto University Institute
for Advanced Studies), I. Flores (CNIC), J. Lewis (Cancer Research
UK London Research Institute), S. Habu (Tokai University School of
Medicine), T. Gridley (Maine Health Institute for Research) and C.
Brakebusch (Biotech Research and Innovation Centre) for sharing the
Dll4floxed, Notch1floxed, Notch2floxed, Cdh5(PAC)-creERT2, Myc floxed,
Rbpj floxed, p21−/−, Jag1floxed, Dll1floxed, Jag2floxed and Rac1floxed mice.S